53 completed, 4 recruiting, 3 terminated, 2 active not recruiting. 67 Phase 1, 17 Phase 2.
Follow Keratosis: new trials by email Literature Review of Keratosis trials Research Report on Keratosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| 5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C) - Actinic Keratoses | Phase 1 | Not yet recruiting | Cedars-Sinai Medical Center | 96 | 2026-09-01 | 2026-10-05 |
| An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face Investigational drug, Photodynamic therapy - Actinic Keratosis (AK) | Phase 1 | Recruiting | Sun Pharmaceutical Industries Limited | 48 | 2026-08-04 | 2026-08-13 |
| Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum 5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH) - Actinic Keratoses | Phase 1 | Recruiting | West Virginia University | 32 | 2026-02-06 | 2026-04-22 |
| Evaluate RLS-1496 Topical Cream for Actinic Keratosis RLS-1496 1.0% cream - Actinic Keratosis (AK) | Phase 1 / Phase 2 | Active not recruiting | Rubedo Life Sciences, Inc. | 24 | 2026-02-03 | 2026-08-12 |
| A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis. HW211026, Placebo - Actinic Keratosis (AK) | Phase 1 | Recruiting | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 40 | 2025-12-25 | 2026-01-06 |
| Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage Ameluz, Sciton HEROic - Actinic Keratoses, Photodamage | Phase 1 | Completed | Sherrif Ibrahim | 10 | 2025-06-27 | 2026-01-02 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 BCX17725, Placebo - Netherton Syndrome | Phase 1 | Active not recruiting | BioCryst Pharmaceuticals | 76 | 2024-09-26 | 2026-11-06 |
| Trial to Investigate GZ21T in Healthy Volunteers GZ21T - Actinic Keratosis | Phase 1 | Completed | Genzada Pharmaceuticals USA, Inc. | 41 | 2024-08-19 | 2026-01-28 |
| Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome ATR12-351 - Netherton Syndrome | Phase 1 | Completed | Azitra Inc. | 6 | 2024-06-16 | 2026-07-29 |
| Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts | Phase 1 | Terminated | Washington University School of Medicine | 6 | 2024-03-14 | 2026-09-03 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy Imipramine, Vehicle - Imipramine, Photodynamic Therapy | Phase 1 | Recruiting | Wright State University | 24 | 2023-01-19 | 2026-08-20 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 24 | 2022-11-08 | 2023-05-18 |
| A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 64 | 2022-06-20 | 2023-03-06 |
| Comparison of Nicotinamide Treatments for Actinic Keratosis Oral Nicotinamide, topical nicotinamide - Actinic Keratoses | Phase 1 | Completed | Federal University of Rio Grande do Sul | 74 | 2022-02-01 | 2025-09-15 |
| A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome SXR1096 cream, Placebo cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Sixera Pharma | 9 | 2021-12-07 | 2025-12-16 |
| Study to Evaluate Safety and Tolerability of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp BF-200 ALA and red light LED lamp - Actinic Keratosis, Keratosis, Actinic | Phase 1 | Completed | Biofrontera Bioscience GmbH | 112 | 2021-12-01 | 2024-10-17 |
| Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK AVX001 - Actinic Keratoses | Phase 1 / Phase 2 | Unknown | Coegin Pharma AB | 60 | 2021-11-02 | 2022-01-27 |
Showing 20 of 67. Sign in to see all of them.
Keratosis, Actinic (50) · Netherton Syndrome (9) · Skin Neoplasms (3) · Callosities (2) · Ichthyosis (2) · Precancerous Conditions (2) · Skin Diseases (2) · Carcinoma, Basal Cell (1) · Cerebral Palsy (1) · Constipation (1) · Darier Disease (1) · Dermatitis, Atopic (1) · Eczema (1) · Facies (1)
Skin and Connective Tissue Diseases (67) · Skin Diseases (65) · Neoplasms (51) · Precancerous Conditions (48) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Genetic Diseases, Inborn (14) · Congenital Abnormalities (13) · Infant, Newborn, Diseases (13) · Skin Abnormalities (13) · Skin Diseases, Genetic (13) · Ichthyosis (11) · Abnormalities, Multiple (10) · Ichthyosiform Erythroderma, Congenital (10) · Pathological Conditions, Signs and Symptoms (4)
3-ingenyl angelate (8) · Radiotherapy (4) · Fluorouracil (3) · Gels (3) · LEO 43204 (3) · Lidocaine (3) · Prilocaine (3) · Aminolevulinic Acid (2) · BF-200 ALA (2) · Imiquimod (2) · Photochemotherapy (2) · calcipotriene (2) · 1-phenyl-3,3-dimethyltriazene (1) · 5-aminolevulinic acid hexyl ester (1) · ADI PEG20 (1)
LEO Pharma (13) · Peplin (5) · Dong-A University (4) · Daiichi Sankyo (3) · Sun Pharmaceutical Industries, Inc. (3) · Athenex, Inc. (2) · Biofrontera Bioscience GmbH (2) · G&E Herbal Biotechnology Co., LTD (2) · Icahn School of Medicine at Mount Sinai (2) · Wright State University (2) · Aclaris Therapeutics, Inc. (1) · Azitra Inc. (1) · BioCryst Pharmaceuticals (1) · Case Comprehensive Cancer Center (1) · Cedars-Sinai Medical Center (1)
United States (40) · Australia (6) · Germany (5) · France (4) · Canada (3) · South Korea (3) · Netherlands (2) · Sweden (2) · Taiwan (2) · Austria (1) · Brazil (1) · China (1) · Denmark (1) · Finland (1) · Iran (1)
Gary Goldenberg, MD (2) · Jonothan S Dosik, MD (2) · Mark Lebwohl, MD (2) · Mary Spellman, MD (2) · Albert C Yan, MD (1) · Alicia D Bucko, MD (1) · Amy Paller (1) · C. William Hanke, MD (1) · Cameron West (1) · Craig Rohan, MD (1) · Daniel Siegel, MD (1) · David Cutler, MD, FRCP (1) · Douglas Kramer, MD (1)
PMID 24765228, PMID 20083693, PMID 22517769, PMID 24329107, PMID 25584134, PMID 25640401, PMID 26011755, PMID 27612149, PMID 28264612, PMID 29204958, PMID 33196758, PMID 33602313, PMID 34633154, PMID 36198452
2014 (1), 2025 (1), P30CA043703 (1), UL1RR024150 (1)